Elite controllers: A heterogeneous group of HIV-infected patients

References

• Autran B, Descours B, Avettand-Fenoel V, et al. Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011;6:181–187.
   PubMed Web of Science ®Google Scholar
• Cockerham LR, Hatano H. Elite control of HIV: is this the right model for a functional cure? Trends Microbiol. 2015;23:71–75.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27:406–416.
   PubMed Web of Science ®Google Scholar
• Lambotte O, Boufassa F, Madec Y, et al. SEROCO-HEMOCO Study Group. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005;41:1053–1056.
   PubMed Web of Science ®Google Scholar
• Gonzalo-Gil E, Ikediobi U, Sutton RE. Mechanisms of virologic control and clinical Characteristics of HIV+ Elite/Viremic controllers. Yale J Biol Med. 2017;90:245–259.
   PubMed Web of Science ®Google Scholar
• Gurdasani D, Iles L, Dillon DG, et al. A systematic review of definitions of extreme phenotypes of HIV control and progression. AIDS. 2014;28:149–162.
   PubMed Web of Science ®Google Scholar
• Leon A, Perez I, Ruiz-Mateos E, et al. EC and immune pathogenesis working group of the Spanish AIDS research network. Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS. 2016;30:1209–1220.
   PubMed Web of Science ®Google Scholar
• Noel N, Lerolle N, Lécuroux C, et al. ANRS C021 CODEX study group. Immunologic and virologic progression in HIV controllers: the Role of Viral “Blips” and Immune Activation in the ANRS CO21 CODEX Study. PLoS One. 2015;10:e0131922.
   PubMed Web of Science ®Google Scholar
• Bansal A, Sterrett S, Erdmann N, et al. Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts. AIDS. 2015;29:2245–2254.
   PubMed Web of Science ®Google Scholar
• Boufassa F, Saez-Cirion A, Lechenadec J, et al. ANRS EP36 HIV Controllers Study Group. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One. 2011;6:e18726.
   PubMed Web of Science ®Google Scholar
• Madec Y, Boufassa F, Porter K, et al. CASCADE Collaboration in Eurocoord. Natural history of HIV-control since seroconversion. AIDS. 2013;27:2451–2460.
   PubMedGoogle Scholar
• Grabar S, Selinger-Leneman H, Abgrall S, et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS. 2009;23:1163–1169.
   PubMed Web of Science ®Google Scholar
• Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis. 2009;200:984–990.
   PubMed Web of Science ®Google Scholar
• Hatano H, Delwart EL, Norris PJ, et al. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009;83:329–335.
   PubMed Web of Science ®Google Scholar
• Dinoso JB, Kim SY, Siliciano RF, et al. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis. 2008;47:102–104.
   PubMed Web of Science ®Google Scholar
• O’Connell KA, Brennan TP, Bailey JR, et al. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. J Virol. 2010;84(14):7018–7028. .
   PubMed Web of Science ®Google Scholar
• Madec Y, Boufassa F, Porter K, et al. CASCADE Collaboration. Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS. 2005;19:2001–2007.
   PubMed Web of Science ®Google Scholar
• Okulicz JF, Marconi VC, Landrum ML, et al. Infectious disease clinical research program (IDCRP) HIV working group. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009;200:1714–1723.
   PubMed Web of Science ®Google Scholar
• Miura T, Brumme ZL, Brockman MA, et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol. 2010;84:7581–7591.
   PubMed Web of Science ®Google Scholar
• Goujard C, Chaix ML, Lambotte O, et al. Agence Nationale de Recherche sur le Sida PRIMO study group. Spontaneous control of viral replication during primary HIV infection: when is “HIV controller” status established? Clin Infect Dis. 2009;49:982–986.
   PubMed Web of Science ®Google Scholar
• Goulder P, Deeks SG. HIV control: is getting there the same as staying there? PLoS Pathog. 2018;14:e1007222.
   PubMed Web of Science ®Google Scholar
• Sajadi MM, Constantine NT, Mann DL, et al. Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors. J Acquir Immune Defic Syndr. 2009;50:403–408.
   PubMed Web of Science ®Google Scholar
• Casado C, Galvez C, Pernas M, et al. Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. Sci Rep. 2020;10(1):1902.
   PubMed Web of Science ®Google Scholar
• Casado C, Marrero-Hernández S, Márquez-Arce D, et al. Viral characteristics associated with the clinical nonprogressor phenotype are inherited by viruses from a cluster of HIV-1 elite controllers. MBio. 2018;9:e02338–17.
   PubMed Web of Science ®Google Scholar
• Pernas M, Tarancón-Diez L, Rodríguez-Gallego E, et al. ECRIS integrated in the Spanish AIDS research network. Factors leading to the loss of natural elite control of HIV-1 infection. J Virol. 2018;92:e01805-17.
   PubMedGoogle Scholar
• Rosás-Umbert M, Llano A, Bellido R, et al. Mechanisms of abrupt loss of virus control in a cohort of previous HIV controllers. J Virol. 2019;93:e01436-18.
   Google Scholar
• Rachinger A, Navis M, van Assen S, et al. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. Clin Infect Dis. 2008;47:e86–9.
   PubMed Web of Science ®Google Scholar
• Pernas M, Casado C, Arcones C, et al. Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller. PLoS One. 2012;7:e31928.
   PubMed Web of Science ®Google Scholar
• Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008;197:126–133.
   PubMed Web of Science ®Google Scholar
• Andrade A, Bailey JR, Xu J, et al. CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load. Clin Infect Dis. 2008;46:78–82.
   PubMed Web of Science ®Google Scholar
• Grabar S, Selinger-Leneman H, Abgrall S, et al. Loss of long-term non-progressor and HIV controller status over time in the french hospital database on HIV - ANRS CO4. PLoS One. 2017;12:e0184441.
   PubMed Web of Science ®Google Scholar
• Benito JM, Ortiz MC, León A, et al. ECRIS integrated in the Spanish AIDS Research Network. Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. BMC Med. 2018;16:30.
   PubMed Web of Science ®Google Scholar
• Crowell TA, Hatano H. Clinical outcomes and antiretroviral therapy in “elite” controllers: a review of the literature. J Virus Erad. 2015;1:72–77.
   PubMed Web of Science ®Google Scholar
• Crowell TA, Gebo KA, Blankson JN, et al. HIV research network. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV Infection. J Infect Dis. 2015;211:1692–1702.
   PubMed Web of Science ®Google Scholar
• Okulicz JF, Boufassa F, Costagliola D, et al. Cancers in elite controllers: appropriate follow-up is essential. AIDS. 2016;30:1852–1855.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009;23:1059–1067.
   PubMed Web of Science ®Google Scholar
• Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012;26:2409–2412.
   PubMed Web of Science ®Google Scholar
• Lucero C, Torres B, León A, et al. Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 Cells/mm3. AIDS Res Hum Retrovir. 2013;29:1161–1167.
   PubMed Web of Science ®Google Scholar
• Dominguez-Molina B, Leon A, Rodriguez C, et al. Spanish AIDS Research network HIV controllers Cohort (ECRIS). Analysis of non-AIDS-defining events in HIV controllers. Clin Infect Dis. 2016;62:1304–1309.
   PubMed Web of Science ®Google Scholar